The present study investigated the serotonin-induced increase in phosphoinositide hydrolysis and mobilization of intracellular Ca 2ϩ ([Ca 2ϩ ] i ) in human uterine smooth muscle cells (HUSMCs) to identify the serotonergic receptor positively coupled to phospholipase C in these cells. In phosphoinositide (PI) assays, serotonin (5-HT) and ␣-methyl-5-HT were potent, full agonists (EC 50 ϭ 20 and 4.1 nM, respectively), whereas the phenyleth- Serotonin (5-hydroxytryptamine, 5-HT) is known to exert a wide variety of physiological actions through its interaction with an extensive family of 5-HT cell surface receptors (Hoyer et al., 1994 (Hoyer et al., , 2002 . In particular, the 5-HT 2 receptor family comprises three subtypes, 5-HT 2A , 5-HT 2B , and 5-HT 2C , which have been reported to play a major role in a host of central nervous system functions including anxiety, depression, migraine, obesity, and schizophrenia. Due to the involvement of 5-HT 2 receptor signaling in these disorders, there has been an increased interest in the therapeutic potential of selective 5-HT 2 ligands as antidepressants, antiobesity drugs, and anxiolytic agents (Hoyer et al., 1994; . Further studies have identified serotonin in human aqueous humor (Veglio et al., 1998) and functionally coupled 5-HT 2 receptors in rat retinal pigment epithelial cells (Osborne et al., 1993) and bovine ciliary epithelium (Inoue-Matsuhisa et al., 2003) .
mobilization assays (r ϭ 0.9, p Ͻ 0.005) in the HUSMC and with contraction of rat stomach fundus strips that contain a 5-HT 2B receptor (r ϭ 0.9, p Ͻ 0.001). Antagonist studies revealed that a 5-HT 2B -selective antagonist, RS-127445 [2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine] (K i ϭ 0.13 nM), was significantly more effective at inhibiting 5-HT-induced activity than a 5-HT 2A antagonist, M-100907 (R-(ϩ)-␣-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol]) (K i ϭ 914 nM) and the 5-HT 2C antagonists RS-102221 (8-[5-(2,4-dimethoxy-5 -(4-trifluoromethylsulfo-amido)phenyl-5-oxopentyl]-1, 3,8-triazaspiro[4.5] decane-2,4-dione hydrochloride) (K i ϭ 2.5 M) and SB-242084 (6-chloro-5-methyl-1-[6-92-methylpyridin-3-yloxy) pyridine-3-ylcarbamoyl] indoline) (K i ϭ 42.4 nM) in the HUSMC PI turnover assays. Taken together, these studies strongly suggest the presence of a functionally active 5-HT 2B receptor subtype in HUSMCs. The physiological role of this receptor in these cells remains to be defined.
Serotonin (5-hydroxytryptamine, 5-HT) is known to exert a wide variety of physiological actions through its interaction with an extensive family of 5-HT cell surface receptors (Hoyer et al., 1994 (Hoyer et al., , 2002 . In particular, the 5-HT 2 receptor family comprises three subtypes, 5-HT 2A , 5-HT 2B , and 5-HT 2C , which have been reported to play a major role in a host of central nervous system functions including anxiety, depression, migraine, obesity, and schizophrenia. Due to the involvement of 5-HT 2 receptor signaling in these disorders, there has been an increased interest in the therapeutic potential of selective 5-HT 2 ligands as antidepressants, antiobesity drugs, and anxiolytic agents (Hoyer et al., 1994; . Further studies have identified serotonin in human aqueous humor (Veglio et al., 1998) and functionally coupled 5-HT 2 receptors in rat retinal pigment epithelial cells (Osborne et al., 1993) and bovine ciliary epithelium (Inoue-Matsuhisa et al., 2003) .
These findings suggested a possible role of serotonin and its receptors in aqueous humor dynamics and as a possible target for ocular pathologies. Indeed, it has recently been shown that topical ocular administration of 5-HT 2 receptor agonists effectively lowered intraocular pressure in a nonhuman primate model of laser-induced ocular hypertension (May et al., 2003) , suggesting a potential utility of 5-HT 2 agonists as antiglaucoma therapeutics. However, the current lack of subtype-selective ligands, especially agonists, has made it difficult to ascribe the hypotensive action of these molecules to an individual 5-HT 2 receptor subtype.
drawn from the U.S. market because of its association with valvular heart disease (Connolly et al., 1997) . Norfenfluramine, the active metabolite of fenfluramine, has been implicated as the causative agent in the observed valvular hyperplasia due to its apparent activity at the 5-HT 2B receptor (Fitzgerald et al., 2000) , although other biological activities of norfenfluramine have not been ruled out. Because of the potential for unwanted side effects using nonselective agonists, there is great interest in developing 5-HT 2 receptor subtype-specific therapeutics that are devoid of 5-HT 2B receptor agonist activity.
We sought to identify cell systems endogenously expressing human 5-HT 2 receptor subtypes to characterize compounds of interest at these therapeutically important receptors. Although compound characterization using cell types with endogenous receptors can be confounded by competing activities at other receptor types, the resulting pharmacology at physiological expression levels and with the native Gprotein coupling system may give a more relevant profile than the use of cell lines overexpressing receptors and/or promiscuous G-protein systems. The 5-HT 2 receptor subtypes are implicated in serotonin-induced smooth muscle contraction and resulting constriction, presumably through G q -coupled activation of phospholipase C, PI hydrolysis, and intracellular calcium mobilization. For example, 5-HT 2A receptors have been identified in vascular smooth muscle tissue and cells where activation of 2A receptors induces tissue contraction and vasoconstriction. 5-HT 2B receptors are highly expressed in rat stomach fundus, and contraction of rat fundic strips is a prototypic assay used to characterize functional agonist activity of compounds at the 5HT 2B receptor (Baxter et al., 1994) . We tested commercially available cell lines for PI metabolism in response to 5-HT and other prototypic serotonergic compounds. Through our search, we discovered that 5-HT and other agonists induced a reproducible PI turnover response and mobilized intracellular calcium in a human uterine smooth muscle cell (HUSMC). In this study, we describe the pharmacological profile of the 5-HT 2 receptor present in HUSMC using prototypic serotonergic agonists and reported subtype-selective 5-HT 2 receptor antagonists. 
Materials and Methods

Materials/Chemicals
5-Hydroxytryptamine hydrochloride, ␣-methyl-5-hydroxytrypta- mine maleate, R-(Ϫ)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopro- pane hydrochloride (R-DOI),
Cell Culture
HUSMCs (catalog no. CC-2562) were obtained from Cambrex (Walkersville, MD). Cell culture media, antibiotics, and trypsin-EDTA were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum was obtained from Hyclone Laboratories (Logan, UT), heatinactivated at 56°C for 30 min, and stored at Ϫ20°C. HUSMCs were cultured in Dulbecco's modified Eagle's medium containing 4.5 g/l glucose, 110 mg/l sodium pyruvate, pyridoxine hydrochloride, and GlutaMax I, supplemented with 10% fetal bovine serum and 10 g/ml gentamicin sulfate.
In Vitro Functional Assays
Phosphoinositide Hydrolysis Assay. Phosphoinositide hydrolysis (PI turnover) assays of phospholipase C activity were conducted by measurement of the agonist-stimulated production of [ 3 H]inositol phosphates from [
3 H]myoinositol as described previously (Sharif and Xu, 1996; Griffin et al., 1998) . In brief, confluent monolayers of human uterine smooth muscle cells were exposed for 24 to 30 h to 1 to 1. 3 H]inositol phosphate was determined by liquid scintillation counting on a beta counter at ϳ50% efficiency (LS6000; Beckman Instruments, Carlsbad, CA). Apparent inhibition constants (K i ) values for the functional antagonist experiments using phosphoinositide hydrolysis were calculated from the determined 50% inhibition concentrations (IC 50 values) as described elsewhere (Cheng and Prusoff, 1973) .
Intracellular Calcium Mobilization Assay. Intracellular calcium mobilization [Ca 2ϩ ] i induced by 5-HT and other serotonergic compounds in HUSMCs was studied using a FLIPR instrument (Molecular Devices) (Schroeder and Neagle, 1996) . Evaluation of the functional agonist activity of test compounds was performed using a protocol described previously (Kelly et al., 2003; May et al., 2003) . In brief, confluent cell monolayers of human uterine smooth muscle cells were trypsinized, pelleted, and seeded at a density of 20,000 cells per well in black-walled, 96-well tissue culture plates and grown to confluence. The fluorescence response of HUSMCs was enhanced by growing the cells in medium containing 10% dialyzed fetal bovine serum for 2 to 3 days followed by incubation in serumfree medium overnight before the experiment. For the experiment, cells were loaded with a calcium-sensitive fluorescent dye provided in a calcium assay kit (Molecular Devices). The dye was reconstituted in FLIPR buffer (Hanks' balanced salt solution buffered with 20 mM HEPES, pH 7.4, 2.5 mM probenecid) and incubated with cells at 23°C for 1 h. Test compounds were diluted in 25% dimethyl sulfoxide/25% ethanol, and further dilutions were prepared in FLIPR buffer and evaluated in concentration-response formats. Agoniststimulated intracellular calcium mobilization was measured on a FLIPR I system monitoring real-time changes in cellular fluorescence ( ex ϭ 488 nm, em ϭ 540 nm) upon agonist additions. Calibration of the instrument was performed using manufacturer's standard procedures. 
Results
Phosphoinositide Hydrolysis Agonist Studies. In phosphoinositide hydrolysis (PI turnover) experiments using [ 3 H]myoinositol, treatment of HUSMC monolayers with 5-HT and other prototypic serotonergic compounds consistently resulted in a production of [ 3 H]inositol phosphates. This agonist-stimulated generation of inositol phosphates suggested the presence of G q -coupled 5-HT 2 receptors in the HUSMC. To further characterize the 5-HT 2 receptor subtype(s) responsible for the observed PI turnover, prototypic serotonergic agonists with some reported 5-HT 2 receptor subtype selectivity were analyzed in concentration-response format using the PI turnover assay in HUSMC. 5-HT and nonselective and reportedly subtype-selective 5-HT 2 agonists induced the activation of phospholipase C and subsequent inositol phosphate generation in a concentration-dependent manner (Fig. 1, A and B) . Tested compounds were then compared and ranked based on the functional potencies determined from the concentration-response curves ( Table 1) . The nonselective natural ligand, 5-HT, was a potent, full agonist (EC 50 ϭ 20 Ϯ 2.8 nM, E max ϭ 105 Ϯ 6%), whereas ␣-methyl-5-HT exhibited approximately 5-fold stronger potency than 5-HT (EC 50 ϭ 4.1 Ϯ 2.1 nM, E max ϭ 93 Ϯ 12%) in the assay. The tryptamine analog BW-723C86, described as a 5-HT 2B -selective agonist, exhibited strong agonist potency and efficacy comparable with 5-HT (EC 50 ϭ 18 Ϯ 2.5 nM, E max ϭ 104 Ϯ 4%). The phenylethylamine ligand R-DOI, considered to be a relatively selective and potent 5-HT 2A receptor agonist, was a full agonist with a modest potency weaker than 5-HT, ␣-methyl-5-HT, and BW-723C86. The piperazines mCPP and MK-212 exhibited functional potencies of 110 Ϯ 32 and 880 Ϯ 320 nM, respectively, with mCPP consistently displaying partial agonist efficacy (E max ϭ 37 Ϯ 5%). MK-212 had the weakest potency of the compounds tested. The (ϩ)-and (Ϫ)-isomers of norfenfluramine, the active metabolite of fenfluramine, were tested for agonist activity in PI turnover dose response. (ϩ)-Norfenfluramine displayed very good potency comparable with 5-HT and ϳ15-fold better than (Ϫ)-norfenfluramine ( Fig. 1B ; Table 1) .
Intracellular Calcium Mobilization. The human uterine smooth muscle cells were tested for mobilization of intracellular calcium in response to 5-HT and selected serotonergic agonists. As expected, 5-HT at 10 M elicited a rapid increase in relative fluorescence compared with basal fluorescence in HUSMCs indicative of increased intracellular calcium ([Ca 2ϩ ] i ) as monitored in real time using the FLIPR instrument. Surprisingly, the relative fluorescence change measuring calcium mobilization in response to 5-HT and other serotonergic compounds was lower than anticipated based on the robust, consistent phosphoinositide metabolism response in these cells. It was also significantly lower than the 5-HT-induced fluorescence change observed with endogenous 5-HT 2 receptors of rat aortic smooth muscle (A7r5) cells (Doyle et al., 1986; May et al., 2003) . The HUSMCs exhibited good viability and adequate loading of the calciumsensitive dye based on a very robust fluorescence increase in response to 10 M histamine observed in these cells. The consistency and magnitude of the 5-HT-induced [Ca 2ϩ ] i mobilization were improved by growing the cells in media with 10% dialyzed serum for 2 to 3 days and then overnight in serum-free medium before the experiment. All serotonergics tested induced increases in relative fluorescence in HUSMC in a concentration-dependent manner (Figs. 2 and 3, A and  B) , and potency and efficacy values were determined from the generated curve fits ( Table 2 ). The rank order potencies of the tested compounds were similar to those observed using PI hydrolysis as the functional readout. 5-HT and ␣-methyl 5-HT were the most potent agonists in the calcium assay. The potencies of BW-723C86 and (ϩ)-norfenfluramine were weaker than observed in the PI experiments but comparable with the activity of R-DOI. MK-212, mCPP, and (Ϫ)-norfenfluramine were weak agonists for calcium mobilization as they were for PI hydrolysis (EC 50 Ͼ 1 M). mCPP showed partial agonist efficacy in the assay (E max ϭ 54%).
Phosphoinositide Hydrolysis Antagonist Studies. To better characterize the 5-HT 2 receptor subtype responsible for PI hydrolysis in human uterine smooth muscle cells, we tested subtype-selective antagonists for the ability to inhibit the 5-HT-mediated PI metabolism. The agonist activity of a submaximal concentration of 5-HT (30 nM) was challenged using increasing concentrations of the selective 5-HT 2A antagonist, M-100907, the 5-HT 2C -selective antagonists, SB-242084 and RS-102221, and the 5-HT 2B -selective antagonist, RS-127445. All 5-HT 2 receptor antagonists tested inhibited the 5-HT-induced PI hydrolysis in HUSMCs in a concentration-dependent fashion (Fig. 4) . However, there were greater than 2 orders of magnitude separation in potency between RS-127445 and the other antagonists tested. The 5-HT 2B antagonist was by far the most potent inhibitor of the 5-HT agonist response, exhibiting a subnanomolar IC 50 (Fig. 4) . The IC 50 values derived from the antagonist concentrationresponse studies were converted into K i values using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) (Table 3 ). The 5-HT 2C receptor-selective antagonists SB-242084 and RS-102221 were much less effective inhibitors in these cells, producing apparent K i values approximately 400-and Ͼ10,000-fold weaker than the potency of RS-127445, respectively ( Table 3 ). The potent 5-HT 2A receptor antagonist, M-100907, was also a very weak inhibitor of the 5-HT response in this system (K i ϭ 914 nM), which was nearly 10,000-fold weaker than the potency of the 5-HT 2B antagonist.
As mentioned above, the rank order potencies of serotonergic agonists were comparable using either PI hydrolysis or mobilization of intracellular calcium as the functional readout. A correlation plot of pEC 50 data for PI turnover (Table 1) against pEC 50 data for functional Ca 2ϩ mobilization (Table  2) shows a high level of agreement (r ϭ 0.9, p Ͻ 0.005) between these two sets of data (Fig. 5A ). The [Ca 2ϩ ] i mobilization pEC 50 data from the current study in HUSMCs also correlated with previous FLIPR functional data using cloned human 5-HT 2B receptors expressed in CHO-K1 cells (r ϭ 0.84, p Ͻ 0.01) ( Table 2) (Porter et al., 1999) . The functional PI data (pEC 50 ; pK i ), obtained with selected agonists in HUSMCs in the present study, correlated most strongly with the reported functional data (pEC 50 ; pA 2 ) for these same compounds inducing the 5-HT 2B -mediated contraction of rat stomach fundus tissues obtained by Baxter et al. (1994) and Baxter (1996) (r ϭ 0.91, p Ͻ 0.001) (Table 1; Fig. 5B ).
Discussion
Exposure of human uterine smooth muscle cells to 5-HT and other prototypic serotonergic compounds elicited production of [ 3 H]inositol phosphates in PI hydrolysis and triggered mobilization of intracellular calcium consistent with the presence of functional G q -coupled 5-HT 2 receptors in these cells.
A panel of prototypic serotonergic agonists with reported selectivity at the various 5-HT 2 receptor subtypes was profiled using PI turnover and [Ca 2ϩ ] i mobilization assays in HUSMC. There is a paucity of available 5-HT 2 subtypeselective agonists, and the compounds reported in the literature to exhibit selectivity give conflicting results in diverse assay systems. Selectivity is further complicated by observed species-dependent differences in agonist activity (Wainscott et al., 1996) . However, the strong potency of reported 2B-selective agonists and the rank order profile of agonists from our results suggested that a 5-HT 2B receptor was present in human uterine smooth muscle cells.
5-HT and ␣-methyl-5-HT were potent, full agonists as measured by PI turnover and [Ca 2ϩ ] i mobilization in the uterine cells, whereas R-DOI, a prototypic 2A agonist, was less ac- Baxter et al. (1994) and Baxter (1996) . b Rat fundus contraction values were determined at MDS Pharma Services (Taipei, Taiwan). c Schild regression analysis value for inhibition of contraction was obtained from Bonhaus et al. (1999) . tive. Although both 5-HT and ␣-methyl-5-HT are considered nonselective 5-HT 2 agonists, previous studies comparing cloned human 5-HT 2 receptor subtypes have shown ␣-methyl-5-HT and, to a lesser extent, 5-HT to have a propensity to selectively activate 5-HT 2B receptors (Porter et al., 1999; Jerman et al., 2001 ). R-DOI exhibited less activity than might be expected if the receptor was a 5-HT 2A receptor subtype.
The reportedly 5-HT 2C -selective piperazines, mCPP and MK-212, exhibited a weak potency in the agonist assays, and mCPP consistently produced partial efficacy. Our findings are in good agreement with previous studies showing mCPP to be a weak partial agonist at the 2B receptor (Baxter et al., 1994; Porter et al., 1999; Rothman et al., 2000; Vickers et al., 2001) . Others have observed that mCPP displays no intrinsic agonist activity and acts as an antagonist at the cloned human 5-HT 2B receptor (Thomas et al., 1996; Wood et al., 1997) . As a weak partial agonist at the 2B receptor, mCPP may behave as a functional antagonist in some assay systems.
The tryptamine analog BW-723C86 has been shown to be a selective agonist for rat (Baxter, 1996; Vickers et al., 2001) and recombinant human (Porter et al., 1999; Jerman et al., 2001 ) 5-HT 2B receptors, although others have found BW-723C86 to be nonselective in receptor binding (Knight et al., 2004) and functional (Cussac et al., 2002) assays. We found that BW-723C86 was a potent agonist for PI hydrolysis and calcium mobilization in HUSMCs. This result was in contrast to the very weak 5-HT 2 agonist activity of BW-723C86 that we have observed using the same functional assays in A7r5 rat vascular smooth muscle cells and primary human ocular trabecular meshwork cells (unpublished data). Likewise, (ϩ)-and (Ϫ)-norfenfluramine gave functional profiles consistent with the observed 5HT 2B -selective potency reported by Porter et al. (1999) at the cloned human 5-HT 2B receptor and similar to the activities for the norfenfluramine isomers observed by others in a variety of systems (Fitzgerald et al., 2000; Rothman et al., 2000; Setola et al., 2003) . The highagonist potencies of the BW-723C86 compound and (ϩ)-norfenfluramine exhibited here strongly suggested the presence of a 5-HT 2B receptor in the HUSMCs.
A prior study using ketanserin as antagonist suggested that 5-HT 2A receptors mediate a serotonin-dependent collagenase induction in rat uterine smooth muscle (RydelekFitzgerald et al., 1993) , whereas we found evidence of a 2B receptor in human uterine smooth muscle. It would be interesting to test currently available subtype-selective antagonists for the ability to inhibit 5-HT induction of collagenase in rat uterine cells. It is unclear if rat and human uterine smooth muscle express different 5-HT 2 receptor subtypes or possess both 2A and 2B with distinct functions. RydelekFitzgerald et al. (1993) do note that 5-HT induction of collagenase was unique to the uterine smooth muscle because no such response was observed in rat aortic smooth muscle. In human uterine tissue, 5-HT 2B receptor mRNA was expressed at high levels, and the receptor was cloned from uterine cDNA libraries (Kursar et al., 1994) as well as from the human neuroblastoma cell line SH-SY5Y (Schmuck et al., 1994) . The presence of high levels of 5-HT 2B receptor mRNA in human uterine tissue supports our contention that the 5-HT 2 receptor signal transduction we observe in HUSMCs can be attributed to the 5-HT 2B receptor subtype.
5-HT and ␣-methyl-5-HT showed stronger potencies for calcium mobilization than PI hydrolysis, whereas BW-723C86 and the other agonists tested were stronger in PI hydrolysis. The reasons for these discrepancies is unclear, although it is tempting to speculate that the increased potency of the nonselective agonists may involve activity at other 5-HT receptors or a greater role of these agonists for the influx of extracellular calcium. Despite these discrepancies, the rank order potencies of agonists derived from our two functional assays are in close agreement (r ϭ 0.9, p Ͻ 0.005; Fig. 5A ). Agonist functional data from our studies were also compared with existing data in the literature obtained using rat fundus contraction (Table 1) (Baxter et al., 1994) and cloned human 5-HT 2B receptor ( 1999). For a majority of compounds, the potency values were increased in the rat tissue contraction assay versus PI hydrolysis (Table 1) . This is perhaps not surprising considering the inherent differences in assay conditions, including readout, tissue versus cell culture, and potential species differences. In fact, we observed differences in absolute potency within calcium mobilization between cloned and endogenous human 2B receptors (Table 2) , possibly due to differences in receptor density or coupling efficiency. However, our data here are in good agreement with those obtained from cloned human 5-HT 2B receptors (r ϭ 0.84, p Ͻ 0.01) and from rat stomach fundus contraction studies (r ϭ 0.91, p Ͻ 0.001; Fig.  5B ), where endogenous 5HT 2B receptors are present.
Subtype-selective antagonists were used to more clearly define the 5-HT 2 receptor subtype responsible for the observed 5-HT response in HUSMCs. In contrast to the lack of selective 5-HT 2 agonists, potent subtype-specific antagonists are available and routinely used to assign pharmacological actions of potential therapeutics to individual receptor subtypes. M-100907, a potent and selective antagonist for 5-HT 2A receptors (Kehne et al., 1996) , was ineffective as an inhibitor of 5-HT-induced phosphoinositide hydrolysis in HUSMCs (pK i ϭ 6.0). This is 1000-fold weaker than binding affinities reported for M-100907 using cloned human 5-HT 2A receptor, rat cortex tissues, or other 5-HT 2A systems (Kehne et al., 1996) .
Likewise, the 5-HT 2C -selective antagonists RS-102221 (Bonhaus et al., 1997) and SB-242084 (Kennett et al., 1997) weakly inhibited the 5-HT response, exhibiting potencies substantially less than would be expected from a 5-HT 2C -mediated response. Previous studies have identified RS-102221 as a 5-HT 2C -selective compound with nanomolar affinity for human 5-HT 2C receptor (pK i ϭ 8.4) as well as nanomolar antagonist potency in a cell-based microphysiometry assay (pA 2 ϭ 8.1) (Bonhaus et al., 1997) . We found RS-102221 to be a very weak inhibitor of 5-HT action in HUSMCs, with a pK i ϭ 5.6, approximately 300-fold weaker than observed in 5-HT 2C systems. A second 5-HT 2C -specific antagonist, SB-242084, was a more effective inhibitor (pK i ϭ 7.4), yet this potency was 50-to 100-fold weaker than the affinity and potency reported in 5-HT 2C systems and correlated very well with binding affinities reported for this compound at cloned human 5-HT 2B receptors (pK i ϭ 7.0) (Kennett et al., 1997) .
In contrast, the 5-HT 2B receptor antagonist RS-127445 was an extremely potent inhibitor of 5-HT-induced PI turnover in HUSMCs (pK i ϭ 9.9), and these results compared favorably with previous studies where RS-127445 displayed subnanomolar affinity at the 5-HT 2B receptor (pK i ϭ 9.5) and potently inhibited both 5-HT-evoked inositol phosphate formation (pK B ϭ 9.5) as well as increases in intracellular calcium (pIC 50 ϭ 10.4) in cells expressing human recombi- (Bonhaus et al., 1999) . RS-127445 has demonstrated 1000-fold selectivity for the 5-HT 2B subtype over other 5-HT 2 subtypes (Bonhaus et al., 1999) and has recently been identified as the most selective 2B receptor antagonist currently available (Knight et al., 2004) . Taken together, the pharmacological profile of the serotonergic agonists and subtype-selective antagonists presented here, as well as the strong correlation with existing functional data for these compounds in a variety of assay systems, provide compelling evidence for the presence of a functional 5-HT 2B receptor in these cultured human uterine smooth muscle cells. The human uterine smooth muscle cells provide a convenient cell-based system for studying the biochemical and pharmacological properties of a human endogenous 5-HT 2B receptor and allow for profiling the bioactivity of compounds of interest. Fig. 5 . Correlation of the functional agonist and antagonist potencies of selected serotonergic compounds at the putative 5-HT 2B receptors in HUSMC from the present study and functional data from contraction assays in rat stomach fundus. A, correlation of agonist potencies determined from the PI turnover assay with agonist potencies determined using the [Ca 2ϩ ] i mobilization assay. The pEC 50 was calculated as Ϫlog of the EC 50 for each agonist determined in the two assays. B, correlation of functional agonist and antagonist potencies using PI turnover assay in the present study (expressed as pEC 50 ; pK i ) with rat stomach fundus contraction studies (pEC 50 ; pA 2 ) from Baxter et al. (1994) and MDS PanLabs.
